

1

Effective Date: March 4, 2024

Lysozyme, Serum 2012039, LYSO SER		
Specimen Requirements:		
Patient Preparation:		
Collect:	Serum separator tube (SST).	
Specimen Preparation:	Separate serum from cells ASAP or within 2 hours of collect Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.4 mL)	
Transport Temperature:	Refrigerated.	
Unacceptable Conditions:	Hemolyzed, lipemic, icteric, or contaminated specimens.	
Remarks:		
Stability:	After separation from cells: Ambient: Unacceptable; Refrigerated: 5 days; Frozen: 1 month.	
Methodology:	Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)	
Performed:	Sun, Tue, Thu	
Reported:	1-5 days	
Note:	Serum lysozyme levels may be elevated in acute myelomonocytic leukemia (FAB-M4), chronic myelomonocyt leukemia (CMML), and chronic myelocytic leukemia (CML). Increased serum lysozyme activity is present in tuberculosis sarcoidosis, megaloblastic anemias, acute bacterial infectior ulcerative colitis, regional enteritis, and Crohn disease. Elevated serum lysozyme occurs during severe renal insufficiency, renal transplant rejection, urinary tract infectio pyelonephritis, glomerulonephritis, and nephrosis.	
CPT Codes:	85549	
New York DOH Approval Status:	This test is New York DOH approved.	
Interpretive Data:		

ARUP Laboratories | 500 Chipeta Way | Salt Lake City, UT 84108 | 800-522-2787 | aruplab.com

Page 1 of 2

A nonprofis enterprise and its Department of LABORATORIES	f the University of Utab Pathology	Effective Date: March 4, 2024	
Component Interpretation _ysozyme, Serum 2.75 ug/mL or less Negative 2.76 - 4.50 ug/mL Equivocal 4.51 ug/mL or greater Positive			
Reference Interval:			
<u>Test Number</u>	Components	Reference Interval	
Lysozyme, Serum	Less than or equal to	<u>4.50 ug^{2.75} μg</u> /mL	Inserted Cells
			Inserted Cells